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Abstract
Fibrodysplasia ossificans progressiva (FOP) is a severely disabling heritable disorder of connective tissue characterized by
congenital malformations of the great toes and progressive heterotopic ossification that forms qualitatively normal bone
in characteristic extraskeletal sites. The worldwide prevalence is approximately 1/2,000,000. There is no ethnic, racial,
gender, or geographic predilection to FOP. Children who have FOP appear normal at birth except for congenital
malformations of the great toes. During the first decade of life, sporadic episodes of painful soft tissue swellings (flare-ups)
occur which are often precipitated by soft tissue injury, intramuscular injections, viral infection, muscular stretching, falls or
fatigue. These flare-ups transform skeletal muscles, tendons, ligaments, fascia, and aponeuroses into heterotopic bone,
rendering movement impossible. Patients with atypical forms of FOP have been described. They either present with the
classic features of FOP plus one or more atypical features [FOP plus], or present with major variations in one or both of
the two classic defining features of FOP [FOP variants]. Classic FOP is caused by a recurrent activating mutation (617G>A;
R206H) in the gene ACVR1/ALK2 encoding Activin A receptor type I/Activin-like kinase 2, a bone morphogenetic protein
(BMP) type I receptor. Atypical FOP patients also have heterozygous ACVR1 missense mutations in conserved amino acids.
The diagnosis of FOP is made by clinical evaluation. Confirmatory genetic testing is available. Differential diagnosis
includes progressive osseous heteroplasia, osteosarcoma, lymphedema, soft tissue sarcoma, desmoid tumors, aggressive
juvenile fibromatosis, and non-hereditary (acquired) heterotopic ossification. Although most cases of FOP are sporadic
(noninherited mutations), a small number of inherited FOP c a s e ss h o wg e r m l i n et r a n s m i s s i o ni na na u t o s o m a ld o m i n a n t
pattern. At present, there is no definitive treatment, but a brief 4-day course of high-dose corticosteroids, started within
the first 24 hours of a flare-up, may help reduce the intense inflammation and tissue edema seen in the early stages of
the disease. Preventative management is based on prophylactic measures against falls, respiratory decline, and viral
infections. The median lifespan is approximately 40 years of age. Most patients are wheelchair-bound by the end of the
second decade of life and commonly die of complications of thoracic insufficiency syndrome.
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Disease name and synonyms
Fibrodysplasia ossificans progressiva (ORPHA337)
Myositis ossificans progressiva (ORPHA337)
Definition
Fibrodysplasia ossificans progressiva (FOP) (Mendelian
Inheritance in Man [MIM] #135100) [1] is a severely
disabling heritable disorder of connective tissue charac-
terized by congenital malformations of the great toes
(hallux valgus, malformed first metatarsal, and/or mono-
phalangism) (Figure 1) and progressive heterotopic ossi-
fication (HO) that forms qualitatively normal bone in
characteristic extraskeletal sites (Figure 2). Involvement
of dorsal, axial, cranial, and proximal anatomic locations
precede involvement of ventral, appendicular, caudal,
and distal areas of the body.
Epidemiology
FOP is very rare with a worldwide prevalence of
approximately 1 case in 2 million individuals. No ethnic,
racial, or geographic predisposition has been described
[2].
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FOP is the most disabling condition of ectopic skeleto-
genesis. Children who have FOP appear normal at birth
except for congenital malformations of the great toes
(Figures 1 and 3).
Typically, during the first decade of life, sporadic epi-
sodes of painful soft tissue swellings (flare-ups) occur
[3] and are commonly mistaken for tumors (Figure 4)
[4]. Although some exacerbations spontaneously regress,
flare-ups can transform skeletal muscles, tendons, liga-
ments, fascia, and aponeuroses through an endochondral
process into ribbons, sheets, and plates of heterotopic
bone (Figures 2 and 5) that span the joints, lock them
in place, and render movement impossible [5,6]. Pro-
gressive episodes of HO occur in specific anatomic pat-
terns, and are typically seen first in the dorsal, axial,
cranial, and proximal regions of the body and later in
Figure 1 Characteristic malformed great toes and hallux
valgus.
Figure 2 Extensive heterotopic ossification on the back of an
FOP patient.
Figure 3 Anteroposterior radiograph of the feet of a three-year
old child showing symmetrical first toe malformations.
Reprinted from reference 14. Authors retain copyright.
Figure 4 Tumor-like swellings on the back representing early
FOP flare-ups.
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Attempts to remove this heterotopic bone usually lead
to episodes of explosive new bone formation. Trauma
such as minor soft tissue injury, muscular stretching,
over-exertion and fatigue, intramuscular immunizations,
injections for dental work, falls, and influenza-like ill-
nesses can induce flare-ups of the condition. Immobility
is cumulative and most patients are wheelchair-bound
by the end of the second decade of life.
The diaphragm, tongue, and extra-ocular muscles are
spared from HO. Cardiac muscle and smooth muscle
are also spared in FOP. Neck stiffness is an early finding
and can precede the appearance of HO at that site. Cer-
vical spine abnormalities include large posterior ele-
ments, tall narrow vertebral bodies, and fusion of the
facet joints between C2 and C7 [8]. The cervical spine
often becomes ankylosed early in life. Other skeletal fea-
tures associated with FOP are short malformed thumbs,
clinodactyly, short broad femoral necks, and proximal
medial tibial osteochondromas [9-11].
In addition to progressive immobility, other life-threa-
tening complications include severe weight loss follow-
ing ankylosis of the jaw, as well as pneumonia and
right-sided heart failure resulting from thoracic insuffi-
ciency syndrome (TIS) [12]. Features of FOP that contri-
bute to TIS include costovertebral malformations with
orthotopic ankylosis of the costovertebral joints, ossifica-
tion of intercostal muscles, paravertebral muscles and
aponeuroses, as well as progressive spinal deformity
including kyphoscoliosis or thoracic lordosis.
Limb swelling seen with flare-ups may be substantial
and lead to extra-vascular compression of nerves and
tissue lymphatics. Some patients with advanced FOP
involving the lower limbs have venous stasis and/or lym-
phedema. In both scenarios, studies to exclude deep
vein thrombosis may be difficult to obtain and interpret.
Limb swelling is often difficult to treat.
Hearing loss is usually conductive and may be due to
middle ear ossification, but in some patients the hearing
impairment is sensorineural, involving the inner ear,
cochlea, or the auditory nerve [13].
Among patients with FOP-like HO and/or toe malfor-
mations, a small number of patients has clinical features
unusual for FOP [11]. These atypical FOP patients are
categorized as FOP-plus (classic defining features of
FOP plus one or more atypical features) and FOP var-
iants (major variations in one or both of the two classic
defining features of FOP, such as normal great toes or
severe reduction deficits of digits). Atypical features
associated with FOP-plus include intraarticular synovial
osteochondromatosis of hips, degenerative joint disease
of hips, sparse/thin scalp hair (more prominent in sec-
ond decade), mild cognitive impairment, severe growth
retardation, cataracts, retinal detachment, childhood
glaucoma, craniopharygioma, persistence of primary
teeth in adulthood, anatomic abnormalities of the cere-
bellum, diffuse cerebral dysfunction with seizures, poly-
ostotic fibrous dysplasia, primary amenorrhea, aplastic
anemia, hypospadias, and cerebral cavernous malforma-
tions [11].
Aetiology
A large body of work has supported dysregulated bone
morphogenetic protein (BMP) signaling in the patho-
genesis of FOP. A single common heterozygous muta-
tion (617G>A; R206H) has been identified in the
cytoplasmic domain of activin receptor IA/activin-like
kinase 2 (ACVR1/ALK2), a BMP type I receptor, in
affected individuals of five small multigenerational
families and in all sporadically affected individuals with
the features of classic FOP [14]. All atypical FOP
patients have heterozygous ACVR1 missense mutations
in conserved amino acids [11]. Novel ACVR1 mutations
have been described for FOP variants and in two cases
of FOP plus [11]. To date, all ACVR1 mutations evalu-
ated for enhanced BMP signaling are gain-of-function
mutations [11,15].
Mounting evidence suggests that involvement of the
inflammatory component of the immune system plays a
critical role in FOP [16]. The presence of macrophages,
lymphocytes and mast cells in early FOP lesions, macro-
phage and lymphocyte-associated death of skeletal
Figure 5 Three-dimensional reconstructed computed
tomography (CT) scan of the back of a twelve-year old child
showing extensive heterotopic ossification typical of FOP.
Reprinted from reference 14. Authors retain copyright.
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tent timing of flare-ups, and the beneficial response of
early flare-ups to corticosteroids support involvement of
the innate immune system in the pathogenesis of FOP
[17].
Diagnosis and diagnostic methods
Clinical suspicion of FOP early in life on the basis of
malformed great toes can lead to early clinical diagnosis
and the avoidance of harmful diagnostic and treatment
procedures. Routine biochemical evaluations do not
contribute to making the diagnosis. Plain x-rays can
substantiate more subtle great toe abnormalities and the
presence of HO. Abnormal findings on bone scan occur
before HO can be detected by conventional radiography,
but sophisticated imaging studies are generally superflu-
ous from a diagnostic standpoint. Confirmatory genetic
testing is available on a clinical and research basis at
several laboratories [18].
Differential Diagnosis
FOP must be distinguished from other genetic condi-
tions of heterotopic ossification (HO), and nonheredi-
tary (acquired) HO. Progressive osseous heteroplasia
(POH) is a rare genetic condition of progressive HO
defined clinically by cutaneous ossification that usually
presents during childhood and progresses to involve
subcutaneous and deep connective tissues, including
muscle and fascia, in the absence of multiple features of
Albright hereditary osteodystrophy (AHO) or hormone
resistance [19]. FOP is differentiated from POH by con-
genital malformation of the great toes, preosseous
inflammation or “flare-ups” and the lack of cutaneous
ossification.
Acquired HO commonly follows severe trauma, and
can be observed at any age but is rare in young children
[20]. Acquired HO tends to occur at periarticular sites
or at sites of blunt trauma or localized injury.
FOP is commonly misdiagnosed as aggressive juvenile
fibromatosis, lymphedema, or soft tissue sarcoma [4].
Other diagnostic considerations are lymphoma, des-
moids tumors, isolated congenital malformations, bra-
chydactyly (isolated), and juvenile bunions.
Genetic counseling
Most cases of FOP arise as a result of a spontaneous
new mutation. Genetic transmission is autosomal domi-
nant and can be inherited from either parent. Within a
family, inherited FOP can show variable expression. If a
parent has FOP, the chance that a child will inherit FOP
is 50%.
There are substantial life-threatening risks to both the
mother and child that women with FOP might encoun-
ter during pregnancy. Specific risks to the mother
include, but are not limited to: (1) risk of FOP flare-ups
during pregnancy; (2) risk of breathing difficulties dur-
ing the latter part of pregnancy; (3) risk of childbirth
complications not uncommon in mothers without FOP.
[For example, Caesarian section is necessary due to the
pelvic deformity, joint fusions, and decreased plasticity
of the birth canal that will not safely accommodate a
normal vaginal delivery]; (4) risk of the general anesthe-
sia for Caesarian delivery; and (5) risk of phlebitis and
pulmonary embolism. The authors are unaware if the
use of amniocentesis has caused complications in the
mother. Specific risks to the child include, but are not
limited to: (1) risk that the child may have FOP; (2) risk
of prematurity; (3) risk of severe fetal distress; (4) risk of
cerebral palsy; (5) risk of complications from general
anesthesia. At delivery, there should be a team skilled in
resuscitation of high risk infants.
Antenatal diagnosis
Prenatal testing is not routinely available for FOP.
Management including treatment
Flare-ups of FOP are sporadic and unpredictable, with
great individual variability of disease progression.
Preventative measures
In children, restriction of activity to less physically inter-
active play may be helpful to reduce falls, but strict
avoidance of high-risk circumstances is not only imprac-
tical but may also prevent patients from optimizing their
level of function. Restriction of activity also compro-
mises independence and may be unacceptable to
patients. Physical rehabilitation should be focused on
enhancing activities of daily living through approaches
that avoid passive range of motion which could lead to
disease flare-ups.
Acceptable modification of activity, improvement in
household safety, use of ambulatory devices, and use of
protective headgear are all strategies to prevent falls and
minimize injury when falls occur. Prophylactic measures
that minimize respiratory decline (e.g., incentive spiro-
metry) and prevent influenza and pneumonia (i.e.,
appropriate immunizations) may decrease morbidity and
mortality associated with thoracic insufficiency
syndrome.
Intramuscular injections, including immunizations,
must be avoided, but vaccinations administered by sub-
cutaneous injection and routine venipuncture pose little
risk. Great care is necessary in administering dental
care, particularly in avoiding overstretching of the jaw
and intramuscular injections of local anesthetic [21].
Preventive oral and dental health care measures are
essential. Successful anesthesia in mandibular primary
teeth can be achieved by infiltration through the dental
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formed carefully. General anesthesia with awake naso-
tracheal fiberoptic intubation may be needed for dental
care in some patients.
Conductive hearing loss is common and children
should generally have audiology evaluations at least
every other year. Hearing aids can diminish develop-
mental problems in children.
Surgical attempts to remove heterotopic bone will
provoke explosive new bone growth and should not be
attempted.
Pharmacotherapy
Corticosteroids are indicated as first-line treatment at
beginning of flare-ups. A brief 4 day course of high-dose
corticosteroids, started within the first 24 hours of a
flare-up, may help reduce the intense inflammation and
tissue edema seen in the early stages of the disease. The
use of corticosteroids should be restricted to treatment of
flare-ups that affect major joints, the jaw, or the subman-
dibular area. Corticosteroids should not generally be
used for the symptomatic treatment of flare-ups that
involve the back, neck, or trunk due to the long duration
and recurring nature of these flare-ups and the difficulty
in assessing the true onset of such flare-ups. A typical
dose of prednisone is 2 mg/kg/d, administered as a single
daily dose. If a second course of corticosteroids becomes
necessary, this should be followed by a slow taper.
When prednisone is discontinued, a nonsteroidal anti-
inflammatory drug (NSAID) or cox-2 inhibitor (in con-
junction with a leukotriene inhibitor) may be used
symptomatically for the duration of the flare-up. The
use of mast cell inhibitors and aminobisphosphonates
can be used at the physician’s discretion.
Many flare-ups are extremely painful and may require
a brief course of well-monitored narcotic analgesia in
addition to the use of NSAIDs, cox-2 inhibitors, and
oral or intravenous glucocorticoids. The cautious short-
term use of muscle relaxants such as cyclobenzaprine
(Flexeril), metaxalone (Skelaxin), or Lioresal (Baclofen)
may help to decrease muscle spasm and maintain more
functional activity.
For a complete description of medications used in the
treatment of FOP, including dosing and potential major
side effects, refer to the current treatment guidelines at
the International Fibrodysplasia Ossificans Progressiva
Association website [22].
Prognosis
The median lifespan is approximately 40 years of age
[23]. Most patients are wheelchair-bound by the end of
the second decade of life and commonly die of compli-
cations of thoracic insufficiency syndrome [23].
Unresolved questions
T h ed i s c o v e r yo ft h es p e c i f i cF O Pg e n em u t a t i o na n d
the results of preliminary studies over the past several
years show clearly that while the specific ACVR1/ALK2
gene mutation may be necessary to cause heterotopic
ossification in FOP, it is not sufficient for inducing
flare-ups of the disease that lead to progressive and
cumulative disability. The required role of the immune
system, the responses of resident progenitor cells, and
the biochemical aberrations of the soft tissue microen-
vironment all appear to be intimately involved in the
induction of flare-ups and episodic progression of the
disease. The investigation of relevant cells and microen-
vironmental factors is necessary to elucidate the com-
plex pathophysiology of FOP.
Consent
Written informed consent could not be obtained for the
cases illustrated in Figures 1, 2, and 4, since the patients
are untraceable from the photographs taken. We believe
this review contains important clinical examples, which
could not be as effectively made in any other way. We
expect that reasonable persons would not object to the
publication of these photographs since details of each
patient remain anonymous.
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